Vericel Corporation (NASDAQ: VCEL) shares plummeted 5.11% in the intraday trading session on Thursday, despite the company reporting better-than-expected earnings for the fourth quarter of 2024.
The biopharmaceutical company reported quarterly earnings of $0.38 per share, surpassing the analyst consensus estimate of $0.32 by 18.75%. However, Vericel's quarterly sales of $75.38 million missed the analyst consensus estimate of $76.47 million by 1.43%, which may have contributed to the stock's decline.
While Vericel's earnings exceeded expectations, the company's sales miss suggests that its revenue growth may have fallen short of analysts' projections. Investors often closely monitor a company's revenue performance as it can be an indicator of future earnings potential and growth prospects.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.